NFE2L2 and Hutchinson-Gilford progeria syndrome: These findings highlight the potential of modulating miR‐140‐5p expression as a novel therapeutic strategy for HGPS, not only by restoring NRF2 activity and mitigating oxidative stress but also by potentially addressing other aspects of the disease, such as skeletal abnormalities and adipose tissue dysfunction.